Page 12 - Truth Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Moleculin Announces Pricing Of $67.8 Million Underwritten Public Offering 02/03/2021 | 09:31am EDT Send by mail : Message : Required fields HOUSTON, Feb. 3, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced the pricing of an underwritten public offering of an aggregate of 14,273,684 shares of common stock at a public offering price of $4.75 per share. Moleculin has granted the underwriters a 30-day option t...

Moleculin Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model Annamycin shown to reach "sanctuary sites" of cancer News provided by Share this article Share this article HOUSTON, Feb. 2, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that a preclinical study in animals demonstrated a potentially significant therapeutic benefit of Annamycin against metastatic osteosarcoma. This appear...

Moleculin Biotech Announces Reverse Stock Split HOUSTON, Jan. 29, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it filed a certificate of amendment to its certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-6 reverse stock split of its common stock. The reverse stock split will take effect at 5:00 pm (Eastern Time) on January 29, 2021, and the Company's co...

SetPoint Medical Raises $64M in Preferred Stock Financing to Support Pivotal Trial for its Novel Bioelectronic Platform January 27, 2021 09:00 ET | Source: SetPoint Medical SetPoint Medical Valencia, California VALENCIA, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- SetPoint Medical Corporation today announced raising $64M in a Preferred Stock Financing to support its RESET-RA pivotal trial in patients with rheumatoid arthritis (RA). The company is developing its platform for the treatment of chronic, inflammation-mediated autoimmune diseases and is i...

Press release content from Business Wire. The AP news staff was not involved in its creation. Mainstay Medical Announces Key Strategic Hires to Drive Global Commercial Expansion January 25, 2021 GMT DUBLIN--(BUSINESS WIRE)--Jan 25, 2021-- Mainstay Medical Holdings plc (“Mainstay” or the “Company”) today announced recent senior leadership additions as part of its global commercial strategy. These include: Elias Tu as Vice President of U.S. Sales; Derek Matteo as Vice President of Marketing; James Knibbs as Vice President of UK, Ireland, and Australia; Boris Deutschmann as Country Manag...